Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CancersOpen Access

Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJin K. KimAAAshley AldenSKSarah Knaus

Discussion

Loading...

Member takes

Overview

Retrospective case series highlights the role of circulating tumor DNA in detecting minimal residual disease in locally advanced rectal cancer patients, suggesting important clinical implications.

Key Points

  • Circulating tumor DNA testing accurately detected minimal residual disease in patients with locally advanced rectal cancer.
  • In the study, 67% of patients with positive ctDNA required surgery for residual cancer compared to 21% of those with negative ctDNA, showing significant differences.
  • This observational analysis involved 28 patients who underwent ctDNA testing after total neoadjuvant therapy from 2019 to 2023.
  • The findings support the potential use of ctDNA testing for guiding treatment decisions in locally advanced rectal cancer patients.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68c2404eb210217d6479a32ahttps://doi.org/10.3390/cancers17152560
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating Tumor DNA Longitudinal Analysis During Total Neoadjuvant Therapy and Non-operative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial2025
  2. 2Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay2025
  3. 3The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy2025
  4. 4New Parameters That May Predict Tumor Regression and Survival in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer2025
  5. 5Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)2025